ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
37 announcements with these filters
Headline growth is strong: revenue up 30.5% to ₹940 Cr and EBITDA margin 22.8%, above the 21–22% guide. Sequentially, margin, gross margin and PAT all fell, and growth is partly acquired.
Marksans Pharma allotted 56,250 equity shares to employee stock option grantees under its 2024 scheme. Shares were issued on exercise of vested options.
Marksans Pharma reported Q2FY27 revenue of ₹940 crore and H1FY27 PAT of ₹303 crore. EBITDA grew 48% to a record ₹214 crore in the quarter.
Q2FY27 revenue ₹940cr (+30.5% YoY), EBITDA ₹214cr at 22.8% margin (+274bps), PAT ₹143.5cr (+44.8%). H1 PAT ₹303cr; net cash ₹1,095cr; Europe front-end being built.
Marksans Pharma Ltd reported revenue from operations of ₹940.2 Cr (+30.5% YoY) and net profit of ₹143.5 Cr (+44.8% YoY) for Q2 FY27.
Marksans Pharma scheduled its Board meeting for November 4, 2026, to approve Q1/H1 unaudited results. No material decision has been taken yet.
Periodic quarterly shareholding pattern filing for Marksans Pharma Ltd. This document provides the latest breakdown of shareholder categories as mandated by SEBI.
Director Sandra Saldanha gifted 2,28,273 shares of Marksans Pharma Ltd to her daughters in an off-market transaction. This internal transfer reallocates promoter-group equity holdings.
Marksans Pharma intimated shareholders about SEBI's extended special window (Feb 2026–Feb 2027) for re-lodgement of pre-April-2019 physical share transfer deeds. No new business, capital, or operational event is disclosed.
Marksans Pharma Limited conducted its 34th Annual General Meeting on August 27, 2026. Shareholders considered the adoption of FY2025-26 financial statements and a dividend of Rs. 0.90 per share.
Marksans Pharma Ltd. has received an ESG score of 56 from Crisil ESG Ratings & Analytics Ltd for Fiscal 2026.
Strong Q1FY27 performance driven by European growth and acquisitions. Marksans achieved highest-ever quarterly EBITDA and PAT, while crossing INR1,000 Cr cash balance.
Marksans Pharma Ltd reported revenue from operations of ₹840.8 Cr (+35.6% YoY) and net profit of ₹159.4 Cr (+173.9% YoY) for Q1 FY27.
Marksans Pharma Ltd submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The filing details operational and sustainability metrics.
Marksans Pharma Ltd submitted its Annual Report for FY 2025-26. The filing also includes a notice for the 34th Annual General Meeting.
Marksans Pharma Ltd has issued a notice to convene its 34th Annual General Meeting on August 27, 2026. The meeting will be held via video conferencing.
Marksans Pharma delivered record FY26 results, crossing INR 3,000 Cr net income with 20.4% EBITDA margins. Management strategy focuses on diversification across US, UK, and Europe markets with high cash generation.
Marksans Pharma Ltd will hold a board meeting on August 12, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.
Marksans Pharma Ltd. has completed the acquisition of 100% share capital of German entity ABCnow GmbH. This strategic move marks the company's expansion into the German market.
Marksans Pharma Ltd filed its quarterly shareholding pattern as per Regulation 31(1)(b). The report details equity distribution among promoters, institutions, and public shareholders.
Marksans Pharma signed a definitive agreement to acquire ABCnow GmbH for €892,384 (≈ 9.64 Crore INR). The deal, closing by 31 July 2026, gives Marksans a foothold in Europe.
Marksans Pharma recommended a final dividend of Rs. 0.90 per equity share. The record date for payment is fixed as August 20, 2026.
Marksans Pharma Ltd announced its Board meeting outcomes, scheduling the AGM for 27 Aug 2026. A final dividend of ₹0.90 per share was recommended.
Marksans Pharma Ltd has completed the acquisition of QliniQ B.V., obtaining 100% share capital. The transaction expands Marksans' presence in the Netherlands.
India Ratings revised Marksans Pharma's bank loan outlook to Positive from Stable, affirming its IND AA- rating. The upgrade covers facilities worth ₹195.75 Crore.
Marksans Pharma delivered record FY26 performance, crossing ₹3,000cr net income with highest-ever profitability. Strategy focuses on geographic diversification (US, UK, Australia) and transitioning to branded prescription generics.
Marksans Pharma acquired 100% of Netherlands-based QliniQ B.V. for ₹82.98 Crore. The deal strengthens its European distribution and marketing infrastructure for Indian-manufactured products.
Marksans Pharma is acquiring 100% of Netherlands-based QliniQ B.V. for ₹71.25 Crore. The deal strengthens Marksans' European distribution and forward-integration strategy.
Marksans Pharma reported record Q3 FY26 revenue of ₹754cr (up 10.6% YoY) with EBITDA margins expanding to 21.3%. Strategy focuses on UK/US market expansion and new launches.
Marksans Pharma submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The auditor confirmed compliance with SEBI regulations and secretarial standards.